Intravacc nasal COVID-19 vaccine effective in early data

By The Science Advisory Board staff writers

April 7, 2021 -- Preclinical data show Intravacc's SARS-CoV-2 outer membrane vesicle (OMV)-based recombinant spike protein (rSp) nose spray vaccine candidate is effective.

Four groups of mice and four groups of hamsters received two intranasal immunizations on day one and day 21. One group of mice and hamsters received a vaccine based on OMV mixed with rSp (CovOMV), and the other was given a vaccine based on OMV coupled to rSp based on Intravacc's proprietary OMV click technology (CovOMVclick). Blood samples were taken, bodyweight loss was measured, and they were examined for lung lesions on day seven.

In the mice that received the CovOMV, 30% virus neutralizing antibodies were detected. Meanwhile, 90% virus neutralizing antibodies were found in those that received CovOMVclick. Both vaccine candidates induced neutralizing antibodies in hamsters, but levels of antibodies were slightly higher in the animals that received CovOMVclick. Since no lung lesions were detected, intranasal vaccination with both OMV-rSp vaccine candidates resulted in complete protection, according to Intravacc.

These preclinical results will allow the company to quickly advance to a phase I/II clinical trial.

Intravacc completes process development for CVB vaccine candidate
Contract development and manufacturing organization Intravacc reported that it has completed the process development and manufacturing of a polyvalent...
Intravacc receives NIH award to develop enterovirus D68 vaccine
Intravacc has been awarded a $9.4 million contract from the National Institute of Allergy and Infectious Diseases, part of the U.S. National Institutes...
Intravacc RSV vaccine candidate posts phase I trial results
Intravacc released results of a clinical phase I trial evaluating its live attenuated respiratory syncytial virus (RSV) vaccine candidate.
Intravacc, Celonic to jointly develop COVID-19 vaccine
Vaccine development firm Intravacc and biopharmaceutical contract development and manufacturing organization Celonic are teaming up to develop a COVID-19...
Intravacc, Leiden University explore vaccine quality control without animals
Intravacc has collaborated with the Leiden Academic Center for Drug Research at Leiden University to find alternatives to the use of lab animals in vaccine...

Copyright © 2021

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter